Avalyn Pharma key facts
as of Oct 2026- Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases…
- Avalyn Pharma is valued at approximately $155.0M as of Oct 2026, per PrivateMarketView’s mark.
- It has raised $386.7M; the latest was IPO ($100.0M) in Apr 2026.
- Notable investors include F-Prime Capital, Norwest, Eight Roads, Novo Holdings, Catalio Capital Management — 28 tracked in total.
- 3 institutional filers report fund marks on Avalyn Pharma across 7 filings.
- Status: In IPO Registration.
Reported valuation; nothing comparable since.
- ·The complete investor list: 28 names
- ·Watch Avalyn Pharma: the Monday email on marks, rounds and moves
Institutional fund marks on Avalyn Pharma
3 filers · latest Jul 20263 SEC-registered funds reported 7 fair-value marks on Avalyn Pharma between May 2026 and Jul 2026. Filer-level marks and implied $/share are available to Pro members.
Membership and data by Private Market View
Avalyn Pharma funding rounds
No funding rounds for Avalyn Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Avalyn Pharma
28+Avalyn Pharma valuation
Avalyn Pharma is valued at approximately $155 million as of Oct 2026. The figure is set by institutional fund marks.
Recent activity
In the last 90 days, Avalyn Pharma's record added 6 institutional fund marks (latest period Jul 2026).
Institutional holders and vehicles
3 SEC-registered funds reported 7 fair-value marks on Avalyn Pharma between May 2026 and Jul 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.
Avalyn Pharma investors
28 investors are on record for Avalyn Pharma, including F-Prime Capital, Norwest, Eight Roads and Novo Holdings. By type, the record holds 4 hedge funds, 3 venture capital firms and 2 asset managers.
About Avalyn Pharma
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2011
- Employees
- 51
- Website
- avalynpharma.com/
- Ownership
- In IPO Registration
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.